19 results
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
Events in Acute GVHD ... #Pathophys #Honc ... #GVHD #GraftVersusHostDisease ... #NEJM
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
Leading to Chronic GVHD ... #Pathophys #Honc ... #Pharm #GVHD #GraftVersusHostDisease ... Therapeutic #Pathways #NEJM
A Controlled Trial of Erenumab for Episodic Migraine #EBM #Neuro #Erenumab #Migraine #CGRP #VisualAbstract #NEJM
Episodic Migraine #EBM ... #Neuro #Erenumab ... VisualAbstract #NEJM
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM ... #Honc #hemophilia ... VisualAbstract #NEJM
Clinical and Histopathological Findings in Chronic Graft-versus-Host Disease (GVHD). #Clinical #Honc #GVHD #GraftVersusHostDisease #NEJM
Graft-versus-Host Disease (GVHD ... #Clinical #Honc ... #GVHD #GraftVersusHostDisease ... #NEJM
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
Treatment of Acute GVHD ... preclinical models of GVHD ... to reduce acute GVHD ... Pathophysiology #IM #Honc ... Immunosuppression #NEJM
Clinical Features of Acute GVHD. Representative images of clinical features of acute graft-versus-host disease (GVHD) are
Features of Acute GVHD ... graft-versus-host disease (GVHD ... #Clinical #Honc ... #Transplant #GVHD ... GraftVersusHostDisease #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM